Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7678417rdf:typepubmed:Citationlld:pubmed
pubmed-article:7678417lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:7678417lifeskim:mentionsumls-concept:C0009498lld:lifeskim
pubmed-article:7678417lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:7678417lifeskim:mentionsumls-concept:C0017978lld:lifeskim
pubmed-article:7678417lifeskim:mentionsumls-concept:C0596988lld:lifeskim
pubmed-article:7678417lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:7678417lifeskim:mentionsumls-concept:C0036576lld:lifeskim
pubmed-article:7678417lifeskim:mentionsumls-concept:C0443199lld:lifeskim
pubmed-article:7678417lifeskim:mentionsumls-concept:C1705938lld:lifeskim
pubmed-article:7678417lifeskim:mentionsumls-concept:C1527178lld:lifeskim
pubmed-article:7678417lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:7678417lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:7678417pubmed:issue3lld:pubmed
pubmed-article:7678417pubmed:dateCreated1993-2-18lld:pubmed
pubmed-article:7678417pubmed:abstractTextA mouse mammary carcinoma mutant cell line showing a characteristic alteration of glycosphingolipid (GSL) composition, but with unchanged protein glycosylation pattern, was isolated. Parent cell line FM3A/F28-7 is characterized by the predominance of lactosylceramide (LacCer) and virtual absence of more complex GSLs. Mutant cell line FUA169 was isolated after treatment of F28-7 cells with the mutagen N-methyl-N'-nitro-N-nitrosoguanidine and incubation with anti-LacCer monoclonal antibody T5A7 and complement. FUA169 cells were characterized by a dramatic reduction in LacCer and by the presence of a major ganglioside identified as GM3. They also showed high activity of CMP-sialic acid:LacCer 2,3-sialosyltransferase, whereas F28-7 cells had no detectable activity of this enzyme. In contrast to the difference in GSL pattern, F28-7 and FUA169 showed identical protein glycosylation patterns, as evidenced by "Western blotting" with various lectins and surface labeling with galactose oxidase/NaB3H4 and periodate/NaB3H4. Thus, FUA169 is identified as a glycosylation mutant with regard to GM3 expression and will be useful for studies of the functional role of GM3. Growth of FUA169 cells, relative to F28-7 cells, showed greater temperature sensitivity and greater inhibitability based on restriction of growth factors, particularly insulin.lld:pubmed
pubmed-article:7678417pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678417pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678417pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678417pubmed:languageenglld:pubmed
pubmed-article:7678417pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678417pubmed:citationSubsetIMlld:pubmed
pubmed-article:7678417pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678417pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678417pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678417pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678417pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678417pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678417pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678417pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678417pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678417pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678417pubmed:statusMEDLINElld:pubmed
pubmed-article:7678417pubmed:monthJanlld:pubmed
pubmed-article:7678417pubmed:issn0021-9258lld:pubmed
pubmed-article:7678417pubmed:authorpubmed-author:TsujiTTlld:pubmed
pubmed-article:7678417pubmed:authorpubmed-author:HakomoriSSlld:pubmed
pubmed-article:7678417pubmed:authorpubmed-author:TsuruokaTTlld:pubmed
pubmed-article:7678417pubmed:authorpubmed-author:HolmesE HEHlld:pubmed
pubmed-article:7678417pubmed:authorpubmed-author:NojiriHHlld:pubmed
pubmed-article:7678417pubmed:issnTypePrintlld:pubmed
pubmed-article:7678417pubmed:day25lld:pubmed
pubmed-article:7678417pubmed:volume268lld:pubmed
pubmed-article:7678417pubmed:ownerNLMlld:pubmed
pubmed-article:7678417pubmed:authorsCompleteYlld:pubmed
pubmed-article:7678417pubmed:pagination2211-6lld:pubmed
pubmed-article:7678417pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:7678417pubmed:meshHeadingpubmed-meshheading:7678417-...lld:pubmed
pubmed-article:7678417pubmed:meshHeadingpubmed-meshheading:7678417-...lld:pubmed
pubmed-article:7678417pubmed:meshHeadingpubmed-meshheading:7678417-...lld:pubmed
pubmed-article:7678417pubmed:meshHeadingpubmed-meshheading:7678417-...lld:pubmed
pubmed-article:7678417pubmed:meshHeadingpubmed-meshheading:7678417-...lld:pubmed
pubmed-article:7678417pubmed:meshHeadingpubmed-meshheading:7678417-...lld:pubmed
pubmed-article:7678417pubmed:meshHeadingpubmed-meshheading:7678417-...lld:pubmed
pubmed-article:7678417pubmed:meshHeadingpubmed-meshheading:7678417-...lld:pubmed
pubmed-article:7678417pubmed:meshHeadingpubmed-meshheading:7678417-...lld:pubmed
pubmed-article:7678417pubmed:meshHeadingpubmed-meshheading:7678417-...lld:pubmed
pubmed-article:7678417pubmed:meshHeadingpubmed-meshheading:7678417-...lld:pubmed
pubmed-article:7678417pubmed:meshHeadingpubmed-meshheading:7678417-...lld:pubmed
pubmed-article:7678417pubmed:meshHeadingpubmed-meshheading:7678417-...lld:pubmed
pubmed-article:7678417pubmed:meshHeadingpubmed-meshheading:7678417-...lld:pubmed
pubmed-article:7678417pubmed:meshHeadingpubmed-meshheading:7678417-...lld:pubmed
pubmed-article:7678417pubmed:meshHeadingpubmed-meshheading:7678417-...lld:pubmed
pubmed-article:7678417pubmed:meshHeadingpubmed-meshheading:7678417-...lld:pubmed
pubmed-article:7678417pubmed:year1993lld:pubmed
pubmed-article:7678417pubmed:articleTitleSelection of a mutant cell line based on differential expression of glycosphingolipid, utilizing anti-lactosylceramide antibody and complement.lld:pubmed
pubmed-article:7678417pubmed:affiliationDepartment of Biochemical Oncology/Membrane Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.lld:pubmed
pubmed-article:7678417pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7678417pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7678417lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7678417lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7678417lld:pubmed